BOSTON — Avison Young, the world’s fastest-growing commercial real estate services firm, announced that Juniper Pharmaceuticals has signed a 7,050-square-foot lease at 33 Arch Street in Boston.
and Matt Twombly, a Principal and Vice-President, respectively, in the firm’s Boston office, represented Juniper Pharmaceuticals in the transaction. CBRE represented the landlord, TIAA-CREF.
Juniper Pharmaceuticals, a specialty pharmaceutical company focused on addressing unmet medical needs in women’s health, will move from its current location at 4 Liberty Square later this month.
“Juniper Pharmaceuticals has experienced tremendous growth, doubling in size over the past two years,” comments McFarland. “The new space at 33 Arch Street will help the firm as it continues to expand.”
The 33 Arch Street site is located in the heart of Boston between Downtown Crossing and the Financial District. The property provides outstanding views of the Charles River and Boston Common, as well as convenient access to four branches of the MBTA and South Station.
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women’s health. Juniper has a commercial product, CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies.